Trial Profile

A randomized double-blind placebo controlled Phase 2b Clinical Trial of Lysergic Acid Diethylamide Microdosing in advanced Stage Cancer Patients.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 May 2024 According to a MindBio Therapeutics media release, company expects the results of this Phase 2B trials to be announced in 2025.
20 Dec 2023 According to MindBio Therapeutics media release, if proven effective in this Phase 2B trial, will potentially be accessible to end of life patients under special drug access schemes that permit access to clinical stage experimental drugs before they are approved by regulatory bodies such as the Food & Drug Administration (FDA).
31 Oct 2023 According to MindBio Therapeutics media release, first patient has been dosed in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com